image
Healthcare - Medical - Devices - NASDAQ - US
$ 1.595
-14 %
$ 437 M
Market Cap
-1.09
P/E
1. INTRINSIC VALUE

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company provides PacBio's Systems, which conduct, monitor, and analyse biochemical sequencing reactions; consumable products, including single molecule real-time (SMRT) cells; and various reagent kits designed for specific workflow, such as template preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides.[ Read More ]

The intrinsic value of one PACB stock under the base case scenario is HIDDEN Compared to the current market price of 1.59 USD, Pacific Biosciences of California, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart PACB

image
FINANCIALS
201 M REVENUE
56.29%
-334 M OPERATING INCOME
-9.73%
-307 M NET INCOME
2.39%
-259 M OPERATING CASH FLOW
1.53%
4.6 M INVESTING CASH FLOW
-96.03%
109 M FINANCING CASH FLOW
1031.69%
40 M REVENUE
10.98%
-59.3 M OPERATING INCOME
59.35%
-60.7 M NET INCOME
64.96%
-45.5 M OPERATING CASH FLOW
16.22%
23.1 M INVESTING CASH FLOW
-69.98%
812 K FINANCING CASH FLOW
634.21%
Balance Sheet Decomposition Pacific Biosciences of California, Inc.
image
Current Assets 742 M
Cash & Short-Term Investments 634 M
Receivables 36.6 M
Other Current Assets 71 M
Non-Current Assets 1 B
Long-Term Investments 2.42 M
PP&E 69 M
Other Non-Current Assets 933 M
Current Liabilities 95 M
Accounts Payable 15.1 M
Short-Term Debt 10.1 M
Other Current Liabilities 69.9 M
Non-Current Liabilities 950 M
Long-Term Debt 924 M
Other Non-Current Liabilities 25.8 M
EFFICIENCY
Earnings Waterfall Pacific Biosciences of California, Inc.
image
Revenue 201 M
Cost Of Revenue 148 M
Gross Profit 52.8 M
Operating Expenses 393 M
Operating Income -334 M
Other Expenses -27.7 M
Net Income -307 M
RATIOS
26.32% GROSS MARGIN
26.32%
-166.80% OPERATING MARGIN
-166.80%
-152.97% NET MARGIN
-152.97%
-43.74% ROE
-43.74%
-17.57% ROA
-17.57%
-20.23% ROIC
-20.23%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Pacific Biosciences of California, Inc.
image
Net Income -307 M
Depreciation & Amortization 26.5 M
Capital Expenditures -8.84 M
Stock-Based Compensation 72.1 M
Change in Working Capital -59 M
Others -8.2 M
Free Cash Flow -275 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Pacific Biosciences of California, Inc.
image
Wall Street analysts predict an average 1-year price target for PACB of $3 , with forecasts ranging from a low of $2 to a high of $4 .
PACB Lowest Price Target Wall Street Target
2 USD 25.39%
PACB Average Price Target Wall Street Target
3 USD 88.09%
PACB Highest Price Target Wall Street Target
4 USD 150.78%
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
0 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership Pacific Biosciences of California, Inc.
image
Sold
0-3 MONTHS
249 K USD 3
3-6 MONTHS
73.9 K USD 2
6-9 MONTHS
1.11 M USD 5
9-12 MONTHS
441 K USD 2
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
176 K USD 1
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
1 month ago
Sep 30, 2024
Sell 34.1 K USD
Kim Susan G.
See Remarks
- 19782
1.722 USD
2 months ago
Sep 16, 2024
Sell 173 K USD
HENRY CHRISTIAN O
See Remarks
- 98907
1.746 USD
2 months ago
Aug 19, 2024
Sell 42.6 K USD
Eidel Jeff
See Remarks
- 26760
1.592 USD
3 months ago
Aug 16, 2024
Sell 63.2 K USD
Van Oene Mark
See Remarks
- 38011
1.662 USD
5 months ago
May 20, 2024
Sell 10.7 K USD
Farmer Michele
See Remarks
- 5275
2.03 USD
8 months ago
Mar 06, 2024
Bought 176 K USD
Meline David W
Director
+ 40000
4.404 USD
8 months ago
Mar 04, 2024
Sell 14.5 K USD
Farmer Michele
See Remarks
- 2968
4.871 USD
8 months ago
Mar 04, 2024
Sell 44.7 K USD
Van Oene Mark
See Remarks
- 9186
4.871 USD
8 months ago
Mar 04, 2024
Sell 25.7 K USD
Kim Susan G.
See Remarks
- 5275
4.871 USD
8 months ago
Mar 04, 2024
Sell 69.1 K USD
HENRY CHRISTIAN O
See Remarks
- 14177
4.871 USD
9 months ago
Feb 16, 2024
Sell 200 K USD
Van Oene Mark
See Remarks
- 33560
5.958 USD
9 months ago
Feb 16, 2024
Sell 92.3 K USD
Eidel Jeff
See Remarks
- 15498
5.958 USD
9 months ago
Feb 16, 2024
Sell 134 K USD
Kim Susan G.
See Remarks
- 22496
5.958 USD
8 months ago
Feb 20, 2024
Sell 4.37 K USD
Kim Susan G.
See Remarks
- 831
5.261 USD
9 months ago
Feb 16, 2024
Sell 471 K USD
HENRY CHRISTIAN O
See Remarks
- 79038
5.958 USD
8 months ago
Feb 20, 2024
Sell 10.4 K USD
HENRY CHRISTIAN O
See Remarks
- 1979
5.261 USD
9 months ago
Feb 16, 2024
Sell 45.1 K USD
Farmer Michele
See Remarks
- 7562
5.958 USD
10 months ago
Jan 09, 2024
Sell 241 K USD
Van Oene Mark
See Remarks
- 31012
7.773 USD
11 months ago
Dec 14, 2023
Sell 200 K USD
HENRY CHRISTIAN O
See Remarks
- 20000
10 USD
1 year ago
Sep 29, 2023
Sell 162 K USD
Kim Susan G.
See Remarks
- 19257
8.437 USD
1 year ago
Sep 18, 2023
Sell 980 K USD
HENRY CHRISTIAN O
See Remarks
- 96844
10.122 USD
1 year ago
Sep 11, 2023
Sell 105 K USD
HENRY CHRISTIAN O
See Remarks
- 10000
10.452 USD
1 year ago
Aug 17, 2023
Sell 105 K USD
HENRY CHRISTIAN O
See Remarks
- 10000
10.5 USD
1 year ago
Aug 17, 2023
Sell 275 K USD
Eidel Jeff
See Remarks
- 25936
10.597 USD
1 year ago
Aug 16, 2023
Sell 287 K USD
Van Oene Mark
See Remarks
- 26102
11 USD
1 year ago
May 18, 2023
Sell 65 K USD
Farmer Michele
See Remarks
- 5165
12.59 USD
1 year ago
Mar 15, 2023
Sell 67.1 K USD
Ericson William W.
Director
- 7541
8.9 USD
1 year ago
Mar 03, 2023
Sell 131 K USD
HENRY CHRISTIAN O
See Remarks
- 13769
9.493 USD
1 year ago
Mar 03, 2023
Sell 59.5 K USD
Van Oene Mark
See Remarks
- 6268
9.493 USD
1 year ago
Mar 03, 2023
Sell 47.9 K USD
Kim Susan G.
See Remarks
- 5045
9.493 USD
1 year ago
Mar 03, 2023
Sell 29.9 K USD
Farmer Michele
See Remarks
- 3153
9.493 USD
1 year ago
Feb 17, 2023
Sell 9.32 K USD
Kim Susan G.
See Remarks
- 907
10.271 USD
1 year ago
Feb 17, 2023
Sell 15.7 K USD
HENRY CHRISTIAN O
See Remarks
- 1530
10.271 USD
1 year ago
Jan 10, 2023
Sell 255 K USD
Van Oene Mark
See Remarks
- 26722
9.534 USD
1 year ago
Dec 01, 2022
Sell 488 K USD
HENRY CHRISTIAN O
See Remarks
- 45000
10.844 USD
2 years ago
Sep 29, 2022
Sell 72.8 K USD
Kim Susan G.
See Remarks
- 12968
5.614 USD
2 years ago
May 18, 2022
Sell 19.8 K USD
Farmer Michele
See Remarks
- 3573
5.547 USD
2 years ago
Feb 17, 2022
Sell 11.7 K USD
Kim Susan G.
Chief Financial Officer
- 1062
11.06 USD
2 years ago
Feb 17, 2022
Sell 23.5 K USD
HENRY CHRISTIAN O
President & CEO
- 2122
11.09 USD
2 years ago
Feb 16, 2022
Sell 37.7 K USD
ORDONEZ KATHY
Director
- 3280
11.5 USD
2 years ago
Jan 11, 2022
Sell 590 K USD
Van Oene Mark
Chief Operating Officer
- 41480
14.23 USD
2 years ago
Jan 11, 2022
Sell 282 K USD
Fromen Peter
Chief Commercial Officer
- 19720
14.3 USD
3 years ago
Sep 29, 2021
Sell 522 K USD
Kim Susan G.
Chief Financial Officer
- 20272
25.75 USD
3 years ago
Sep 16, 2021
Sell 2.44 M USD
HENRY CHRISTIAN O
President & CEO
- 90520
26.91 USD
3 years ago
Sep 16, 2021
Sell 2.44 M USD
HENRY CHRISTIAN O
President & CEO
- 90520
26.91 USD
3 years ago
May 25, 2021
Sell 947 K USD
Ericson William W.
Director
- 36600
25.882 USD
3 years ago
May 25, 2021
Sell 23.8 K USD
Ericson William W.
Director
- 900
26.419 USD
3 years ago
Feb 26, 2021
Sell 5.24 M USD
Hunkapiller Michael
Director
- 170824
30.687 USD
3 years ago
Feb 26, 2021
Sell 1.38 M USD
Hunkapiller Michael
Director
- 43946
31.493 USD
3 years ago
Feb 26, 2021
Sell 516 K USD
Hunkapiller Michael
Director
- 15771
32.738 USD
3 years ago
Feb 26, 2021
Sell 123 K USD
Hunkapiller Michael
Director
- 3705
33.33 USD
3 years ago
Feb 25, 2021
Sell 3.43 M USD
Hunkapiller Michael
Director
- 110515
31.045 USD
3 years ago
Feb 24, 2021
Sell 3.11 M USD
Hunkapiller Michael
Director
- 87349
35.586 USD
3 years ago
Feb 24, 2021
Sell 2.02 M USD
Hunkapiller Michael
Director
- 55399
36.413 USD
3 years ago
Feb 25, 2021
Sell 3.94 M USD
Hunkapiller Michael
Director
- 123383
31.971 USD
3 years ago
Feb 25, 2021
Sell 767 K USD
Hunkapiller Michael
Director
- 23331
32.877 USD
3 years ago
Feb 24, 2021
Sell 2.71 M USD
Hunkapiller Michael
Director
- 72303
37.466 USD
3 years ago
Feb 25, 2021
Sell 1.69 M USD
Hunkapiller Michael
Director
- 49410
34.209 USD
3 years ago
Feb 25, 2021
Sell 1.02 M USD
Hunkapiller Michael
Director
- 29500
34.728 USD
3 years ago
Feb 25, 2021
Sell 116 K USD
Hunkapiller Michael
Director
- 3238
35.68 USD
3 years ago
Feb 24, 2021
Sell 1.97 M USD
Hunkapiller Michael
Director
- 51376
38.359 USD
3 years ago
Feb 23, 2021
Sell 745 K USD
Hunkapiller Michael
Director
- 24100
30.898 USD
3 years ago
Feb 23, 2021
Sell 907 K USD
Hunkapiller Michael
Director
- 28595
31.706 USD
3 years ago
Feb 23, 2021
Sell 602 K USD
Hunkapiller Michael
Director
- 18259
32.975 USD
3 years ago
Feb 23, 2021
Sell 1.45 M USD
Hunkapiller Michael
Director
- 42378
34.224 USD
3 years ago
Feb 22, 2021
Sell 2.13 M USD
Hunkapiller Michael
Director
- 57260
37.172 USD
3 years ago
Feb 23, 2021
Sell 3.98 M USD
Hunkapiller Michael
Director
- 113308
35.101 USD
3 years ago
Feb 22, 2021
Sell 1.28 M USD
Hunkapiller Michael
Director
- 33491
38.082 USD
3 years ago
Feb 22, 2021
Sell 1.5 M USD
Hunkapiller Michael
Director
- 38360
39.146 USD
3 years ago
Feb 23, 2021
Sell 2.67 M USD
Hunkapiller Michael
Director
- 74119
35.992 USD
3 years ago
Feb 22, 2021
Sell 2.33 M USD
Hunkapiller Michael
Director
- 57902
40.284 USD
3 years ago
Feb 22, 2021
Sell 1.73 M USD
Hunkapiller Michael
Director
- 42114
41.064 USD
3 years ago
Feb 23, 2021
Sell 2.67 M USD
Hunkapiller Michael
Director
- 72562
36.847 USD
3 years ago
Feb 22, 2021
Sell 151 K USD
Schaefer Eric
Chief Accounting Officer
- 3842
39.2 USD
3 years ago
Feb 16, 2021
Sell 5.65 M USD
ORDONEZ KATHY
Director
- 118667
47.584 USD
3 years ago
Feb 16, 2021
Sell 4.9 M USD
ORDONEZ KATHY
Director
- 101004
48.466 USD
3 years ago
Feb 16, 2021
Sell 53.9 K USD
ORDONEZ KATHY
Director
- 1100
49 USD
3 years ago
Feb 12, 2021
Sell 5.12 M USD
Shapiro Lucy
Director
- 101666
50.4 USD
3 years ago
Feb 12, 2021
Sell 3.24 M USD
LIVINGSTON RANDALL S
Director
- 67500
48.066 USD
3 years ago
Feb 12, 2021
Sell 7.68 M USD
Botstein David
Director
- 154858
49.608 USD
3 years ago
Feb 12, 2021
Sell 258 K USD
Botstein David
Director
- 5142
50.091 USD
3 years ago
Jan 25, 2021
Sell 182 K USD
Hunkapiller Michael
Director
- 5167
35.167 USD
3 years ago
Jan 25, 2021
Sell 3 M USD
Hunkapiller Michael
Director
- 83241
36.006 USD
3 years ago
Jan 25, 2021
Sell 1.19 M USD
Hunkapiller Michael
Director
- 32082
37.166 USD
3 years ago
Jan 25, 2021
Sell 186 K USD
Hunkapiller Michael
Director
- 4916
37.766 USD
3 years ago
Jan 21, 2021
Sell 1.03 M USD
Hunkapiller Michael
Director
- 29049
35.436 USD
3 years ago
Jan 20, 2021
Sell 5.48 M USD
Hunkapiller Michael
Director
- 141199
38.789 USD
3 years ago
Jan 21, 2021
Sell 4.13 M USD
Hunkapiller Michael
Director
- 113472
36.392 USD
3 years ago
Jan 22, 2021
Sell 1.62 M USD
Hunkapiller Michael
Director
- 45165
35.916 USD
3 years ago
Jan 20, 2021
Sell 1.73 M USD
Hunkapiller Michael
Director
- 43846
39.345 USD
3 years ago
Jan 20, 2021
Sell 978 K USD
Hunkapiller Michael
Director
- 24032
40.69 USD
3 years ago
Jan 21, 2021
Sell 2.3 M USD
Hunkapiller Michael
Director
- 61834
37.18 USD
3 years ago
Jan 21, 2021
Sell 26.6 K USD
Hunkapiller Michael
Director
- 700
38.055 USD
3 years ago
Jan 21, 2021
Sell 143 K USD
Hunkapiller Michael
Director
- 3656
39.085 USD
3 years ago
Jan 20, 2021
Sell 246 K USD
Hunkapiller Michael
Director
- 5949
41.405 USD
3 years ago
Jan 22, 2021
Sell 2.6 M USD
Hunkapiller Michael
Director
- 70377
36.948 USD
3 years ago
Jan 21, 2021
Sell 865 K USD
Hunkapiller Michael
Director
- 23817
36.303 USD
3 years ago
Jan 21, 2021
Sell 965 K USD
Hunkapiller Michael
Director
- 25993
37.128 USD
3 years ago
Jan 22, 2021
Sell 1.33 M USD
Hunkapiller Michael
Director
- 35315
37.521 USD
3 years ago
Dec 21, 2020
Sell 283 K USD
Hunkapiller Michael
Director
- 13870
20.378 USD
3 years ago
Dec 21, 2020
Sell 360 K USD
Hunkapiller Michael
Director
- 16698
21.549 USD
3 years ago
Dec 22, 2020
Sell 1.57 M USD
Hunkapiller Michael
Director
- 64195
24.392 USD
3 years ago
Dec 21, 2020
Sell 1.2 M USD
Hunkapiller Michael
Director
- 52923
22.675 USD
3 years ago
Dec 22, 2020
Sell 4.38 M USD
Hunkapiller Michael
Director
- 172242
25.412 USD
3 years ago
Dec 22, 2020
Sell 2.38 M USD
Hunkapiller Michael
Director
- 90459
26.336 USD
3 years ago
Dec 21, 2020
Sell 5.67 M USD
Hunkapiller Michael
Director
- 243544
23.287 USD
3 years ago
Dec 22, 2020
Sell 1.01 M USD
Hunkapiller Michael
Director
- 37555
26.908 USD
3 years ago
Dec 21, 2020
Sell 204 K USD
Hunkapiller Michael
Director
- 8514
24.01 USD
3 years ago
Nov 24, 2020
Sell 21.5 K USD
Hunkapiller Michael
Director
- 1492
14.385 USD
3 years ago
Nov 20, 2020
Sell 2.23 M USD
Hunkapiller Michael
Director
- 147799
15.112 USD
3 years ago
Nov 23, 2020
Sell 3.79 M USD
Hunkapiller Michael
Director
- 251837
15.032 USD
4 years ago
Nov 18, 2020
Sell 603 K USD
Hunkapiller Michael
Director
- 38381
15.711 USD
3 years ago
Nov 19, 2020
Sell 34.2 K USD
Hunkapiller Michael
Director
- 2201
15.55 USD
4 years ago
Nov 16, 2020
Sell 675 K USD
Hunkapiller Michael
Director
- 42488
15.895 USD
4 years ago
Nov 10, 2020
Sell 18.6 M USD
Hunkapiller Michael
Director
- 1304348
14.25 USD
4 years ago
Nov 11, 2020
Sell 2.79 M USD
Hunkapiller Michael
Director
- 195652
14.25 USD
4 years ago
Nov 11, 2020
Sell 4.12 M USD
Hunkapiller Michael
Director
- 250000
16.464 USD
4 years ago
Nov 12, 2020
Sell 3.35 M USD
Hunkapiller Michael
Director
- 200000
16.729 USD
4 years ago
Aug 24, 2020
Sell 1.72 M USD
Hunkapiller Michael
CEO & President
- 259164
6.6347 USD
4 years ago
Aug 25, 2020
Sell 1.47 M USD
Hunkapiller Michael
CEO & President
- 228632
6.441 USD
4 years ago
Aug 20, 2020
Sell 1.66 M USD
Hunkapiller Michael
CEO & President
- 256554
6.4696 USD
4 years ago
Aug 21, 2020
Sell 1.25 M USD
Hunkapiller Michael
CEO & President
- 189847
6.568 USD
4 years ago
Mar 24, 2020
Sell 8.42 K USD
Phillips James Michael
SVP, Research & Development
- 2760
3.051 USD
4 years ago
Feb 19, 2020
Sell 55.8 K USD
BARNES SUSAN K
EVP, CFO and PAO
- 12558
4.44 USD
4 years ago
Feb 20, 2020
Sell 22.6 K USD
Phillips James Michael
SVP, Research & Development
- 5050
4.48 USD
4 years ago
Feb 20, 2020
Sell 750 K USD
Hunkapiller Michael
Chairman, CEO & President
- 166575
4.501 USD
4 years ago
Feb 18, 2020
Sell 2.36 M USD
Hunkapiller Michael
Chairman, CEO & President
- 525995
4.493 USD
4 years ago
Feb 19, 2020
Sell 342 K USD
Hunkapiller Michael
Chairman, CEO & President
- 76281
4.488 USD
5 years ago
Feb 19, 2019
Sell 51.8 K USD
Phillips James Michael
SVP, Research & Development
- 7231
7.166 USD
5 years ago
Feb 19, 2019
Sell 49.7 K USD
ORDONEZ KATHY
Director
- 6933
7.168 USD
5 years ago
Feb 19, 2019
Sell 85.9 K USD
BARNES SUSAN K
EVP, CFO and PAO
- 11987
7.162 USD
5 years ago
Feb 19, 2019
Sell 95.8 K USD
Hunkapiller Michael
Chairman, CEO & President
- 13335
7.186 USD
5 years ago
Nov 27, 2018
Sell 188 K USD
ORDONEZ KATHY
Chief Commercial Officer
- 25000
7.54 USD
8 years ago
Oct 28, 2016
Sell 169 K USD
Phillips James Michael
SVP, Research & Development
- 20000
8.436 USD
8 years ago
Jul 29, 2016
Sell 169 K USD
Phillips James Michael
SVP, Research & Development
- 20000
8.446 USD
8 years ago
Apr 25, 2016
Sell 206 K USD
Phillips James Michael
SVP, Research & Development
- 20000
10.286 USD
9 years ago
Aug 07, 2015
Sell 77 K USD
Phillips James Michael
SVP, Research & Development
- 16689
4.6144 USD
9 years ago
Mar 02, 2015
Bought 9.22 K USD
Phillips James Michael
SVP, Research & Development
+ 1877
4.913 USD
9 years ago
Mar 02, 2015
Bought 13.8 K USD
CORCORAN KEVIN P
SVP, Market Development
+ 2816
4.913 USD
9 years ago
Mar 02, 2015
Bought 12.3 K USD
Dow Brian B
VP and PAO
+ 2503
4.913 USD
10 years ago
Aug 11, 2014
Bought 698 K USD
Ericson William W.
Director
+ 143300
4.8703 USD
10 years ago
Aug 08, 2014
Bought 252 K USD
Ericson William W.
Director
+ 51423
4.8957 USD
10 years ago
Aug 07, 2014
Bought 698 K USD
Ericson William W.
Director
+ 146265
4.7731 USD
10 years ago
Aug 06, 2014
Bought 117 K USD
Ericson William W.
Director
+ 24761
4.7367 USD
10 years ago
Aug 05, 2014
Bought 530 K USD
Ericson William W.
Director
+ 114321
4.6395 USD
10 years ago
Jun 12, 2014
Bought 274 K USD
Ericson William W.
Director
+ 45875
5.9679 USD
10 years ago
Jun 10, 2014
Bought 359 K USD
Ericson William W.
Director
+ 68921
5.2112 USD
10 years ago
Aug 19, 2014
Bought 202 K USD
Ericson William W.
Director
+ 39299
5.1398 USD
10 years ago
Aug 18, 2014
Bought 687 K USD
Ericson William W.
Director
+ 135155
5.0867 USD
10 years ago
Aug 14, 2014
Bought 389 K USD
Ericson William W.
Director
+ 77822
4.9954 USD
10 years ago
Aug 13, 2014
Bought 145 K USD
Ericson William W.
Director
+ 29435
4.9252 USD
10 years ago
Aug 12, 2014
Bought 604 K USD
Ericson William W.
Director
+ 123423
4.8935 USD
10 years ago
Dec 12, 2013
Bought 229 K USD
Hunkapiller Michael
Chairman, CEO & President
+ 55087
4.1574 USD
10 years ago
Dec 11, 2013
Bought 184 K USD
Hunkapiller Michael
Chairman, CEO & President
+ 44913
4.0971 USD
10 years ago
Nov 21, 2013
Bought 722 K USD
Hunkapiller Michael
Chairman, CEO & President
+ 200000
3.6084 USD
11 years ago
Dec 03, 2012
Bought 99 K USD
Hunkapiller Michael
Chairman, CEO & President
+ 56700
1.7455 USD
11 years ago
Nov 30, 2012
Bought 171 K USD
Hunkapiller Michael
Chairman, CEO & President
+ 97400
1.7585 USD
11 years ago
Nov 29, 2012
Bought 169 K USD
Hunkapiller Michael
Chairman, CEO & President
+ 97400
1.7368 USD
11 years ago
Nov 28, 2012
Bought 164 K USD
Hunkapiller Michael
Chairman, CEO & President
+ 97400
1.682 USD
11 years ago
Nov 27, 2012
Bought 73.6 K USD
Hunkapiller Michael
Chairman, CEO & President
+ 47400
1.5535 USD
11 years ago
Nov 26, 2012
Bought 145 K USD
Hunkapiller Michael
Chairman, CEO & President
+ 97400
1.4918 USD
11 years ago
Nov 23, 2012
Bought 72.3 K USD
Hunkapiller Michael
Chairman, CEO & President
+ 50000
1.4468 USD
11 years ago
Nov 21, 2012
Bought 51.6 K USD
Hunkapiller Michael
Chairman, CEO & President
+ 39000
1.323 USD
12 years ago
Nov 20, 2012
Bought 83.3 K USD
Hunkapiller Michael
Chairman, CEO & President
+ 65600
1.2693 USD
12 years ago
Nov 19, 2012
Bought 113 K USD
Hunkapiller Michael
Chairman, CEO & President
+ 89400
1.2623 USD
12 years ago
Nov 16, 2012
Bought 121 K USD
Hunkapiller Michael
Chairman, CEO & President
+ 100000
1.2119 USD
12 years ago
Nov 15, 2012
Bought 169 K USD
Hunkapiller Michael
Chairman, CEO & President
+ 150000
1.1235 USD
12 years ago
Nov 14, 2012
Bought 13.9 K USD
Hunkapiller Michael
Chairman, CEO & President
+ 12300
1.1297 USD
12 years ago
Aug 07, 2012
Bought 608 K USD
Hunkapiller Michael
Chairman, CEO & President
+ 347500
1.75 USD
12 years ago
Aug 06, 2012
Bought 91.7 K USD
Hunkapiller Michael
Chairman, CEO & President
+ 52500
1.7459 USD
7. News
Pacific Biosciences' Cost Cuts Won't Offset Rising Competition Pacific Biosciences of California stock surged 50% since August despite a 24% YoY revenue decline and deteriorating gross margins due to increased costs and pricing pressures. Q3 revenue of $40 million missed analyst estimates, with SG&A expenses surpassing total revenue and gross profit margins remaining low at 28%. Pacific Biosciences has made significant cuts in R&D, which may harm long-term growth given the rapid technological advancements in the genomic market. seekingalpha.com - 4 days ago
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought The rock star money manager is starting to roll with the rallying market. fool.com - 4 days ago
PacBio price target lowered to $6 from $7 at Scotiabank Scotiabank lowered the firm's price target on PacBio to $6 from $7 and keeps an Outperform rating on the shares. The firm lowered its FY24 and FY25 revenue estimates following the company's Q3 update, the analyst tells investors. The firm's longer-term outlook for the company, however, remains intact, believing the company is highly differentiated and the recently accelerated pace of product innovations place the company in a good position for outsized growth. https://thefly.com - 6 days ago
PacBio to Present at Upcoming Investor Conferences MENLO PARK, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will be participating in the following upcoming investor conferences: globenewswire.com - 1 week ago
PACB Stock Falls Despite Q3 Earnings Beat, Revenues Decline Y/Y PacBio Q3 2024 revenues decline year over year. However, Consumable, and Service and other revenues increase. zacks.com - 1 week ago
Pacific Biosciences of California, Inc. (PACB) Q3 2024 Earnings Call Transcript Pacific Biosciences of California, Inc. (NASDAQ:PACB ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Todd Friedman - Senior Director of Investor Relations Christian Henry - President and Chief Executive Officer Susan Kim - Chief Financial Officer Conference Call Participants Tejas Savant - Morgan Stanley Kyle Nixon - Canaccord Mason Carrico - Stephens Dan Brennan - TD Cowen Jack Meehan - Nephron Research Subbu Nambi - Guggenheim Securities Madeline Mollman - Wolfe Research Operator Good day and welcome to the PacBio Third Quarter 2024 Earnings Conference Call. All participants will be in a listen-only mode. seekingalpha.com - 1 week ago
Pacific Biosciences (PACB) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates The headline numbers for Pacific Biosciences (PACB) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. zacks.com - 1 week ago
Pacific Biosciences of California (PACB) Reports Q3 Loss, Misses Revenue Estimates Pacific Biosciences of California (PACB) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares to loss of $0.27 per share a year ago. zacks.com - 1 week ago
PacBio Announces a Private Convertible Exchange Transaction of $459 Million Principal Amount of 1.50% Convertible Senior Notes due 2028 MENLO PARK, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced that it has entered into a privately negotiated exchange agreement with a holder of PacBio's remaining outstanding 1.50% Convertible Senior Notes due 2028 (the “2028 Notes”), pursuant to which PacBio will (i) issue $200 million principal amount of its 1.50% Convertible Senior Notes due 2029 (the “New Notes”), (ii) issue 20,451,570 shares (the “Shares”) of PacBio's common stock (“common stock”), and (iii) make a cash payment in the amount of $50 million (the “Cash Consideration”) in exchange for $459 million principal amount of the 2028 Notes (the “Exchange Transaction”), in a transaction exempt from registration under the Securities Act of 1933, as amended, and the rules and regulations thereunder. The Exchange Transaction is expected to close on or about November 21, 2024, subject to customary closing conditions. globenewswire.com - 1 week ago
PacBio Unveils the Vega System, a New Sequencing Platform Bringing HiFi to the Benchtop Priced at just $169,000 Vega is designed to make highly accurate long-read sequencing accessible to any laboratory Priced at just $169,000 Vega is designed to make highly accurate long-read sequencing accessible to any laboratory globenewswire.com - 1 week ago
The Schall Law Firm Encourages Investors With Losses To Join An Inquiry Into Pacific Biosciences of California Inc For Fraud LOS ANGELES, CA / ACCESSWIRE / November 4, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Pacific Biosciences of California, Inc. ("PacBio" or "the Company") (NASDAQ:PACB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. accesswire.com - 1 week ago
Pacific Biosciences of California, Inc. Is Being Investigated For Securities Law Violations And Affected Shareholders Are Urged To Contact The Schall Law Firm LOS ANGELES, CA / ACCESSWIRE / November 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Pacific Biosciences of California, Inc. ("PacBio" or "the Company") (NASDAQ:PACB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. accesswire.com - 2 weeks ago
8. Profile Summary

Pacific Biosciences of California, Inc. PACB

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 437 M
Dividend Yield 0.00%
Description Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company provides PacBio's Systems, which conduct, monitor, and analyse biochemical sequencing reactions; consumable products, including single molecule real-time (SMRT) cells; and various reagent kits designed for specific workflow, such as template preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. The company serves research institutions; commercial laboratories; genome centers; public health labs, hospitals and clinical research institutes, contract research organizations, and academic institutions; pharmaceutical companies; and agricultural companies. It markets its products through a direct sales force in North America and Europe, as well as through distribution partners in Asia, Europe, the Middle East, Africa, and Latin America. Pacific Biosciences of California, Inc. has a development and commercialization agreement with Invitae Corporation. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.
Contact 1305 O’Brien Drive, Menlo Park, CA, 94025 https://www.pacb.com
IPO Date Oct. 27, 2010
Employees 796
Officers Ms. Natalie Welch Chief People Officer Mr. Christian O. Henry M.B.A. President, Chief Executive Officer & Director Ms. Michele Farmer CPA Vice President & Chief Accounting Officer Dr. Brett Atkins J.D., Ph.D. General Counsel & Corporate Secretary Dr. Stephen Turner Ph.D. Co-Founder Ms. Susan G. Kim Chief Financial Officer Mr. Jeff Eidel Chief Commercial Officer